Latest Regulatory Approvals News

Star Minerals secures shareholder approval for its Cobra Uranium Project in Namibia and prepares for maiden drilling, while progressing gold exploration in Western Australia amid a modest capital raise.

Island Pharmaceuticals has enrolled all subjects in the Phase 2b arm of its ISLA-101 dengue fever clinical trial, advancing its antiviral drug development with key results expected in 2025.

Element 25 Limited has announced a 107% increase in Ore Reserves at its Butcherbird Manganese Project in Western Australia, now supporting an 18.3-year mine life at 1.1Mtpa production. This milestone underpins the company’s strategic expansion into battery-grade manganese supply for the EV market.

Amcor plc has entered a definitive agreement to acquire Berry Global Group in a $9.9 billion all-stock transaction, aiming to create a global packaging leader. The merger, pending shareholder and regulatory approvals, is expected to close mid-2025.

Evolution Mining delivered a standout December quarter with record cash flows, improved safety, and regulatory approval extending Cowal’s mine life to 2042. The company’s growth projects, including the Mungari mill expansion, are progressing ahead of schedule and under budget, positioning Evolution strongly for FY25.

LTR Pharma has inked a national distribution agreement with Symbion, positioning its innovative ED treatment SPONTAN® for broad pharmacy access across Australia ahead of its commercial launch.

FMR Resources has secured GroundTruth Drilling to commence a 1,500m RC drilling campaign at its Fairfield Copper Project in New Brunswick, targeting high-grade copper-silver zones and new anomalies identified by airborne EM surveys.

Sabre Resources Ltd has identified four new uranium chargeability anomalies at its Dingo Project in the Northern Territory, expanding its exploration potential in the Ngalia Basin. The company plans to drill test these targets pending regulatory approval.

Buru Energy is progressing steadily on its Rafael Project, aiming for commercial agreements in early 2025 and production by late 2027, while implementing significant cost reductions to sharpen its financial position.

Recce Pharmaceuticals has successfully dosed all patients in its Phase II trial of RECCE® 327 topical gel for acute bacterial skin infections, showing encouraging preliminary efficacy and safety data. The company is preparing for pivotal Phase III trials in Australia and Indonesia, targeting a significant global market opportunity.

Delta Lithium reports strong drilling results and successful metallurgical test work at its Yinnetharra Lithium Project, underpinning confidence in resource expansion and future development plans.

New Frontier Minerals has entered a strategic alliance with Austral Resources to process copper ore from its Big One Deposit, aiming to accelerate production and exploration in the Mt Isa copper belt.